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Introduction: Diabetes is one of the leading causes of both morbidity and mortality
worldwide and is a pressing concern since these figures are on the rise. The International
Diabetes Federation indicated that approximately 463 million adults currently have diabetes
globally, with an additional 374 million individuals living in prediabetic state (IDF, 2019).
Diabetes is also at the forefront with regard to costs in that it has risen from $245 billion in 2012
(American Diabetes Association, 2018) to an estimated $327 billion in 2017—the latter of which
is comprised of $237 billion in direct medical costs along with the remaining $90 billion incurred
as a result of absenteeism, a reduced ability to work, and a general reduction in overall
productivity (American Diabetes Association, 2018). While the transition from a state of
prediabetes (i.e., impaired glucose tolerance) to overt diabetes has been heavily studied, there is a
dearth of existing literature targeting the reversal from a state of impaired glucose tolerance
(IGT) to one of normal glucose tolerance (NGT). Preventative measures undertaken to
circumvent the likelihood of developing type 2 diabetes can more adeptly be accomplished by
transitioning from a state of IGT back to a state of NGT before it is too late. Evaluating
cardiovascular, glucoregulatory, lifestyle, and demographic characteristics along with urinary
biomarkers, the baseline lipid profile, and anthropometric measures occurring amongst subjects
in a state of IGT at baseline may shed light on potential predictors involved in the reversal back
to NGT.

i

Aim: The goal of this study is to evaluate the possible predictors that may incite the
regression from a state of impaired glucose tolerance (IGT) to one of normal glucose tolerance
(NGT).
Methods: This study analyzed existing epidemiological data from the total insulin
resistance atherosclerosis study (IRAS) cohort of 1,625 participants using an exploratory data
analysis (EDA) approach. This study evaluated only participants with Impaired Glucose
Tolerance (IGT) when measured at baseline (n=303). Subjects who transitioned from IGT to
NGT (n=81) were compared to those who remained in a state of IGT during both visits (n=121)
along with subjects who progressed from IGT to a state of overt type 2 diabetes at follow-up
(n=101). Group differences for continuous and categorical variables were assessed using the
Wilcoxon Rank Sum/Kruskal Wallis chi-square tests, respectively.
Results: Male participants were more likely to experience a successful reversal from a
state of IGT to one of NGT compared to their female peers. Menopausal status was a statistically
significant characteristic serving as an impediment in the transition from a state of IGT to one of
NGT. Subjects with elevated BMIs were significantly less likely to reverse from IGT to NGT
compared to those with lower BMIs.
Conclusion: The results suggest that female participants are less likely to experience a
reversal from a state of impaired glucose tolerance to one of normal glucose tolerance compared
to male participants. This finding appears to be contingent upon menopausal status when
measured during both baseline and follow-up visits, respectively.
Keywords: normal glucose tolerance, impaired glucose tolerance, type 2 diabetes,
prediabetes reversal.
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Chapter I
Introduction
1.1 Background
Prediabetes is an intermediate stage between normal glucose regulation and the onset of
type 2 diabetes, which is problematic in that it leads to increased risks for the development of
diabetes mellitus along with the potential onset of vascular complications [1]. More specifically,
worldwide estimates obtained by the International Diabetes Federation indicate that while nearly
463 million adults are currently living with diabetes, another 374 million adults are also
prediabetic [2]. While this figure is already high, the anticipated global diabetes prevalence is
projected to rise to 700 million by 2045 alone, which is why it is imperative that the precursors
and biomarkers that may lead up to this are discovered and addressed. Despite the existence of
randomized controlled trials (RCTs) that have demonstrated relative success in preventing the
progression from prediabetes to type 2 diabetes, they were nonetheless limited in that they
considered lifestyle factors or pharmacological interventions only. Unfortunately, these two
methods alone are problematic in that medications lose efficacy upon discontinuation, and
lifestyle modification is effective solely upon the condition that it becomes an ingrained habit
that is interwoven into the fabric of one’s daily routine.
Moreover, while lifestyle intervention protocols have been more effective in terms of
preventing or mitigating the progression from prediabetes to type 2 diabetes, this is not the case
with respect to the reversal of a state of impaired glucose tolerance (IGT) back to one of normal
glucose tolerance (NGT) instead. This poses a challenge due to the lack of extant studies that
have deliberately focused upon the pre-specified reversal of prediabetes and the restoration of
normal glucose regulation as a primary outcome of interest. The lack of research in this area is of
11

concern due to the emerging evidence indicating that the reversal of prediabetes to a state of
NGT is highly important. This reversal confers benefits that include protection from the future
development of diabetes, the minimization of complications stemming from this state, along with
the provision of an increased likelihood of longevity during the long-term follow-up of subjects.
Given that prediabetes is an intermediary step towards the onset of type 2 diabetes,
understanding the complex interplay involved in the transition is necessary to tailor interventions
to those at risk before this rare window of opportunity closes. Extant research has found that
some of the notable predictors that are accountable for the transition from normal glucose
regulation to prediabetes include variables such as being male, older in age, having a higher
BMI, living with a larger waist circumference, along with having a higher conglomeration of
total fat and abdominal adipose tissue [3, 4, 5, 6, 7, 8]. Moreover, participants with higher fasting
plasma glucose (FPG) and two-hour plasma glucose (2hrPG) levels are also more prone towards
the eventual onset of prediabetes; this is in accompaniment to factors such as having lower levels
of insulin sensitivity, insulin secretion, and disposition index [5].
Moreover, additional variables affiliated with the transition from normal glucose
regulation to prediabetes include higher baseline plasma levels of LDL, cholesterol, and of
triglycerides occurring in tandem with a lower level of HDL cholesterol [6, 7, 8]. The
implication of these findings similarly resonates with respect to the reversal of prediabetes and
the restoration of normal glucose regulation as well. More specifically, participants with lower
baseline levels of FPG and of 2hrPG, who were younger in age, experienced greater insulin
secretion, and who encountered weight loss were more likely to regress from a prediabetic state
to one of NGT instead [9]. The primary body of research in this area is composed of RCTs that
have investigated lifestyle and/or medication interventions with varying degrees of success. As a
12

result, this study goes one step further by evaluating the changes occurring over time with
respect to measures of adiposity, the lipid profile, cardiovascular characteristics, glucoregulatory
mechanisms, metabolites, along with anthropometric, lifestyle, and demographic characteristics
of interest. In addition, the inclusion of F2 – Isoprostanes into this comprehensive list of factors is
a novelty that will hopefully shed light upon that which may lead to the successful regression
from prediabetes back to a state of NGT.1 Increasing our knowledge base on the underpinnings
of a reversal from IGT to NGT can hopefully aid by increasing awareness, reducing the
proliferation of diabetic comorbidities, and can hopefully save lives through a reduction of future
risks, such as (but not limited to) cardiovascular disease (CVD) and premature mortality.
1.2 Purpose of the Study
The existing landscape illustrates that while a large amount of research has been
conducted with respect to the evaluation of the progression from a state of IGT to the eventual
onset of type 2 diabetes, there is a dearth of studies that examine the reversal of prediabetes to a
state of normal glucose regulation. Despite the existence of several RCTs that demonstrate the
utility behind lifestyle interventions and of pharmacological agents, they nonetheless focus
specifically upon preventing the progression from prediabetes to type 2 diabetes [1]. As a result,
few studies have evaluated the pre-specified reversal of prediabetes as a primary outcome of
interest.
While the review undertaken by Sallar and Dagogo-Jack in 2020 is the most current and
comprehensive analysis of the existing body of research in this area [1], this study takes it one
step further by addressing some of the incongruous findings emerging with respect to participant
characteristics, such as demographic, adiposity, and glucoregulatory measures along with
1

amongst participants in a state of IGT at baseline when followed over time for five years.
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differences in plasma lipid and amino acid levels. As a result, the purpose of this study is to
determine which factors (if any) are associated with the regression from prediabetes to a state of
normal glucose tolerance (NGT) in participants when compared to those who either remained
prediabetic or else progressed entirely to a state of diabetes when evaluated over a five-year time
frame.
While extant research has evaluated the impact of plasma lipid and amino acid levels
along with glucoregulatory, adiposity, and demographic measures separately, this paper is
novelty in that no study has fully explored the impact that these variables may have upon the
reversal of impaired glucose tolerance (IGT) to normal glucose tolerance (NGT) when all of
these factors are evaluated simultaneously. By accounting for as many variables as possible, this
study attempts to investigate which ones might be associated with a regression from prediabetes
to normal glucose regulation by using the Insulin Resistance Atherosclerosis Study (IRAS),
which was the first epidemiologic study of its kind that was used and designed with the intention
of analyzing relationships between insulin resistance, glycemia, insulinemia, diabetes, and
ultimately of cardiovascular disease (CVD) within the context of a large multiethnic cohort [10].
In turn, the IRAS dataset provides a wealth of information through which to examine changes in
glucose tolerance status over time due to its prospective cohort design.
1.3 Research questions and hypotheses
1). What is the impact of sex, ethnicity, menopausal status, and age in years on the reversal from
a state of Impaired Glucose Tolerance back to one of Normal Glucose Tolerance?
2). What is the impact of weight, BMI, waist circumference, and waist/hip ratio on the reversal
from a state of IGT back to one of NGT?
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3.) What is the impact of Fasting Insulin, 2-Hr Insulin, Insulin Sensitivity, AIR, Fasting Glucose,
2-Hr Glucose, and Glucose Effectiveness on the potential for reversal from a state of IGT to one
of NGT?
4.) What is the impact of Total Cholesterol, LDL, HDL, and Triglyceride levels, along with each
specific F2-Isoprostane/BMI ratio on the potential for reversal from a state of IGT to one of
NGT?
5.) What is the impact of Hypertension, the Ankle/Brachial Index, Systolic BP, Diastolic BP,
Mean CCA, and Mean ICA on the potential for reversal from a state of IGT to one of NGT?
6.) What is the impact of Smoking Status, Total Energy Expended, High Energy Expended, and
Moderate Energy Expended on the potential for reversal from a state of IGT to one of NGT?
7.) What is the impact of urine creatinine and urine albumin on the potential for reversal from a
state of IGT to one of NGT?
1.4 Thesis Organization
This thesis is organized into five chapters. Chapter I consists of an introduction of the
issue accompanied by relevant background information, the purpose of the study, and
subsequently includes the research questions and their respective hypotheses. The literature
review is presented in Chapter II. The methods utilized, a description of the sample used, and the
measures of interest are all described in Chapter III. Chapter IV is composed of the findings and
outcomes associated with the study. Lastly, Chapter V consists of the discussion, a description of
the strengths and of any potential limitations, and it in turn concludes with recommendations.
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Chapter II: Literature Review
2.1 The Relationship between Glucose Homeostasis and the Progression of Diabetes
Diabetes is one of the leading causes of both mortality and morbidity worldwide,
accompanied by cancer, heart disease and stroke. In the United States alone, 34.2 million
Americans live with diabetes with another 88 million who are prediabetic, which attests to the
enormity of this ever-increasing problem [11]. Diabetes also is at the forefront with regard to
expenses in that by 2017, the costs associated with diabetes had steadily increased to an
estimated $327 billion. While this figure is primarily composed of $237 billion in direct medical
costs alone, the remaining $90 billion arose as a function of absenteeism, a lessened ability to
work, along with a general reduction in overall productivity [12]. Diabetes is also a pressing
concern worldwide; the International Diabetes Federation (IDF) illustrated that approximately
463 million adults currently have diabetes, with an additional 374 million individuals living in a
prediabetic state as of 2019 alone [2].
These figures are on the rise; projections from the International Diabetes Federation
anticipate that the global diabetes prevalence is expected to increase to approximately 700
million by 2045 [2]. Prospective studies indicate that risk factors associated with the onset of
type 2 diabetes include a propensity towards being overweight/obese accompanied by a lack of
physical activity [13, 14, 15]. These findings illustrate the extent to which a low level of physical
activity—when in conjunction with obesity-- is associated with impaired glucose tolerance and
the eventual onset of type 2 diabetes [15]. Additional research by Hu et. al in 2004 further
underscores this link in that researchers concluded that exercise and type 2 diabetes are inversely
associated [16]. More specifically, subjects with impaired glucose regulation experienced a
nearly five-fold increase in the acquisition of diabetes when compared to participants with
16

normal glucose levels [16]. To combat the dangers associated with the onset of diabetes mellitus,
researchers encourage lifestyle changes (such as alterations made with respect to diet and
physical activity) as one approach through which to mitigate potential risk factors associated
with disease progression [17].
While much attention is paid to the role of insulin, the onset of type 2 diabetes arises in
part due to IGT, which is a disturbance in normal glucose homeostasis that subsequently leads to
abnormal glucose regulation. This abnormality is a metabolic disruption that may enable the
inception of intermediates-- IGT and impaired fasting glucose (IFG)--which may in turn lead to
the eventual development of diabetes [18]. NGT is comprised of both fasting and 2-hour glucose
concentrations (<140 mg/dl) [13]. IGT is defined as the presence of an elevated 2-hour plasma
glucose concentration (>=140 and <200mg/dl) measured after the ingestion of a 75-gram glucose
load during an oral glucose tolerance test (OGTT) when accompanied by a fasting plasma
glucose concentration of <126mg/dl [13].
2.2 The Relationship between Glucose Effectiveness, Normal Glucose Tolerance (NGT),
Impaired Glucose Tolerance (IGT), and Diabetes
Researchers studying glucose tolerance amongst 827 subjects (out of the initial 1625)
within Insulin Resistance Atherosclerosis Study (IRAS) found a notable trend in that they
discovered that glucose effectiveness, basal insulin effect (BIE), and glucose effectiveness at
zero insulin (GEZI) all deteriorated synchronously with worsening glucose tolerance [19]. This
suggests that subjects with NGT at baseline experienced a decline with respect to BIE, GEZI,
and overall glucose effectiveness (SG) when their status transitioned to either a state of IGT or
else to one of full-blown diabetes [19]. Amongst those with NGT at baseline, the respective
transition to either IGT or else to diabetes was in turn related to declines in SG (P<0.001), BIE
(P=0.009) and GEZI (P<0.001) [19]. This differed starkly in comparison to the findings obtained
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for subjects with IGT at baseline in that longitudinal changes in terms of glucose tolerance status
led to only mildly significant changes with respect to SG (P=0.049) and BIE (P=0.042), whereas
there was no statistically significant change in GEZI (P=0.332). These findings show that despite
subjects reaping the benefits associated with being in a state of NGT, they may nonetheless
experience declines in SG and in GEZI, which accompany a deterioration in glycemic status.
However, this is diametrically opposed to that which occurs amongst those who are prediabetic
(IGT) given that they encounter only modest changes in SG and in GEZI. The only exception to
this occurs with respect to BIE, which worsens at all stages of glucose tolerance.
Consequently, these findings illustrate that while glucose effectiveness (SG) is an
important determinant of glucose metabolism [20], it also serves as a predictor of the
development towards (and the eventual onset) of diabetes [21, 22]. Findings emerging from other
studies indicate that SG is reduced amongst those found to be in either a state of IGT or else who
are categorized as being diabetic [22, 23]. This suggests that unlike those who are in a state of
NGT, glucose effectiveness may be hard to differentiate in some cases in that it appears to be
similar amongst those with IGT and diabetes [23].
2.3 Biomarkers that underlie the Regression from a Prediabetic State to One of Normal
Glucose Regulation
While the transition from prediabetes to type 2 diabetes (T2D) has been intensively and
abundantly studied, there is a lack of existing research pertaining to the regression from a state of
IGT to one of normal glucose regulation. A review published in 2020 indicated that an increased
focus should be placed upon the restoration of normal glucose regulation by reversing
prediabetes through long-term follow-up and care [1]. Doing so may in turn mitigate future
mortality and morbidity rates by reducing not only the complications emerging from diabetes but
also by minimizing the risk of dying prematurely [1]. This newly published review from 2020
18

delves into the biomarkers that underlie the transition from NGT (or normoglycemia) to IGT and
that potentially result from changes in factors such as (but not limited to) inflammation,
increased adiposity, metabolomics, and glucoregulatory mechanisms [1]. Due to a wealth of
extant research investigating the transition from a state of normal glucose regulation to either
prediabetes and/or the onset of type 2 diabetes, results indicate that weight gain, deficits in
insulin sensitivity, and alterations in pancreatic beta cell function are largely responsible for the
rapid progression occurring between states of glucose tolerance and of their eventual
deterioration over time.2 Moreover, when accompanied by biological changes to incretin
response that occur alongside changes in inflammatory cytokines and fluctuations in hepatic
glucose production, these events happening in unison shed even more light upon the mechanisms
that may be responsible for declines in health over time [24, 25].
Oxidative stress arises as a result of Reactive Oxygen Species (ROS), which are particles
comprised of highly reactive groups of oxygen-containing molecules. More specifically, these
molecules are produced during normal metabolic processes taking place amongst aerobic
organisms, although the most notable occurrences in which they are generated happen in the
mitochondria through reduction-oxidation reactions [27]. ROS induce damage through their
ability to alter both the structural and functional properties of target molecules due to the manner
in which they react with nucleic acids, proteins, and lipids [26]. ROS-induced oxidative damage
in cells is avoidable when antioxidant defense mechanisms are working properly; a state of redox
homeostasis is upheld when both the ROS levels and the antioxidant defenses are in balance
[31]. However, this state of redox homeostasis is dismantled when there is an insufficient
antioxidant defense system, which subsequently generates oxidative stress within the body. One
2

Along with their eventual deterioration over time.
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method used to measure an individual’s oxidative status is through the utilization and
measurement of biomarkers such as F2-isoprostanes [27]. Polyunsaturated fatty acids easily react
with reactive oxygen species, which in turn produce oxidation products (such as F2-isoprostanes)
that can be easily measured. F2-isoprostanes can serve as a powerful tool with respect to
quantification [27, 28]. The stability of these molecules enables researchers to both capture and
in turn accurately reflect the full extent of the damage —the oxidative injury—occurring in vivo
[30]. F2-Isoprostanes play a critical role in that their elevated levels commonly serve as an
indication of the occurrence of oxidative stress [27, 30]. Despite this, another interpretation is
that these heightened levels may instead reflect the level of functioning with respect to the
mitochondrial metabolism instead; some prospective studies have demonstrated that certain
individuals with higher F2-isoprostane levels nonetheless have a lower risk of diabetes and of
weight gain [29, 31]. In the latter scenario, this relationship can potentially serve as a protective
factor for individuals who are at risk of either developing IGT and/or of acquiring diabetes. More
specifically, the isomer with the highest inverse association for those at risk of IGT and/or of
type 2 diabetes is the 2,3-dinor-iPF2 α -III(F2-isoP) in that its protective effects also appear to be
amplified even amongst those who are obese [29]. Due to the importance of F2-isoprostanes,
their inclusion into this study can help to define the role that they may have (if any) with respect
to IGT, along with the extent to which they may be involved in the reversal from a state of IGT
back to one of NGT.
2.4 The Reversal of Prediabetes and Subsequent Restoration of Normal Glucose Regulation
While the bulk of extant research predominately focuses upon the transition from IGT to
the onset of diabetes, the regression from prediabetes to a state of normal glucose regulation is of
critical importance and should no longer be overlooked. It is preferable to reverse an individual’s
20

condition from a state of prediabetes back to one of normal glucose regulation (NGR) since
doing so can substantially lower the risk of acquiring T2D. A shift from IGT to NGT is
accompanied by the minimization of future diabetes-related complications [1], which attests to
the importance of addressing these health concerns early prior to the commencement and the
eventual manifestation of symptoms. Nonetheless, several landmark RCTs have illustrated the
importance of lifestyle modification interventions3 with regard to health outcomes; researchers
involved in the Malmö study found that after six years of follow up, 52% of subjects with IGT in
the intervention group had successfully reverted back to a state of NGT [32]. This reversion to a
state of normal glucose tolerance was complemented by modifications made in terms of blood
pressure and hyperinsulinemia. This transition similarly led to improvements in the lipid profiles
of the participants and was also accompanied by an amelioration in their overall acute insulin
secretory responses to glucose [32].
A second study known as the Diabetes Prevention Program (DPP) similarly demonstrated
a successful reversal from a state of IGT back to one of NGT amongst participants who were
exposed to a lifestyle-based intervention; over 40% of subjects randomized to the lifestyle
intervention group successfully regressed back to a state of NGT—a feat that is double the rate
of reversal amongst those who were either exposed to the Metformin arm (20%) [9, 33] or else to
the placebo [9, 33] instead. The two aforementioned studies indicated that subjects with a lower
baseline fasting plasma glucose (FPG) and a reduced two-hour plasma glucose (2hrPG) when
measured during an oral glucose tolerance test (OGTT) were more likely to successfully regress
from a state of prediabetes back to one of NGT. Additionally, participants who engaged in
sustained weight loss, who incurred greater insulin secretion, and who were younger in age were
3

When compared to subjects in the placebo group.
21

significantly more likely to experience a reversal from prediabetes to a state of NGR in
approximately 40% of participants, which is an important finding [9, 33]. Overall, both the DPP
and the Malmö study demonstrate the value and the benefits associated with the lifestyle-based
intervention due to the manner in which a regression from prediabetes to a state of NGR was
achieved amongst 40% to 50% of participants [9, 33]. Additional RCTs attempted to evaluate the
influence of pharmacological agents in order to determine their effectiveness in terms of
initiating the regression from a state of IGT to one of NGT amongst participants when measured
either independently or else in conjunction with a lifestyle intervention. One trial involving
randomization to either Acarbose (or else to a placebo) yielded promising initial results in that
over 35% of participants with IGT had successfully reverted to a state of NGT after a three-year
follow-up period.
Despite this, the initially successful regression back to NGT was not sustained in that
many participants unfortunately experienced a glycemic rebound after a mere three months [34].
Two additional RCTs investigated the influence of pharmacological agents within participants by
testing the effects of Orlistat and Rosiglitazone in order to determine their effectiveness with
respect to the initiation of a reversal from a state of IGT to one of NGT. Despite encountering
initial success with around 48% of subjects having converted from a state of IGT to one of NGT,
this gradually dwindled and is likely a testament to a waning in drug efficacy over time [35, 36,
37]. However, the sustained reversal from a state of IGT to one of NGT amongst the participants
who did change their routine health habits and exercise behaviors serves as a testimony to the
importance of lifestyle modifications [37, 38, 39, 40]. This finding contrasts against the results
found for subjects placed on medication alone due to the manner in which their regression and
subsequent ability to remain in a state of NGT was relatively fleeting [37, 38, 39, 40]. A similar
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result from the Malmö study that builds upon this outcome is that after twelve years of followup, the participants who were successfully engaged in some form of a lifestyle modification
experienced a mortality benefit as a result of the sustained intervention [32, 39].
While the substantial weight loss associated with bariatric surgery has led to a greater
likelihood of reversing 4 diabetes along with concomitant improvements made for conditions
such as hypertension and dyslipidemia, this procedure (if undertaken on its own) is by no means
a permanent solution [42]. Even though bariatric surgery can effectively mitigate the incidence
of type 2 diabetes, [41] researchers in one study found that a reassessment occurring within a
ten-year time frame (after the bariatric surgery took place) nonetheless indicated a reappearance
of diabetes in nearly 50 percent of the patients who had previously been in remission [43]. As
such, this finding attests to the slowly declining efficacy associated with bariatric surgery; this is
likely due to the fact that weight loss alone may not be fully sustained unless the patients have
fully incorporated permanent lifestyle modifications into their post-surgery routines.
2.5 The Impact and Benefits of Regression from Prediabetes to Normal Glucose Regulation
Attempts made to incite a reversal from a state of IGT to one of NGT is beneficial and
cost-effective in terms of prevention since it is achievable by non-surgical means. Efforts made
to change habits early are essential in that doing so can minimize both the risks of morbidity and
mortality in a manner that is far less feasible to accomplish upon the onset of type 2 diabetes.
More specifically, prediabetes (i.e., IGT) is a condition that encompasses a wide variety of
vascular complications such as retinopathy, neuropathy, nephropathy, stroke, myocardial
infarction, and even cardiovascular death, all of which may be mitigated with early preventative
efforts [25]. The benefits associated with a clinical regression from a state of prediabetes to NGT
4

or else an amelioration of this.
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cannot be overstated due to the manner in which those who have successfully achieved a state of
normal glucose regulation (NGR) at least one or more times during a longitudinal study were
able to attain a 56% lower risk of incident type 2 diabetes. However, this was not the case
amongst subjects who were consistently prediabetic throughout the entirety of the follow-up
period [43]. These findings subsequently illustrate how the risk reduction for the incidence of
diabetes appear to increase concurrently with the number of times in which a participant was
able to successfully achieve a state of NGR; even transitory states of NGR helped to diminish an
individual’s future risk of developing diabetes [43]. In addition to reducing the onset of type 2
diabetes, successfully regressing back to a state of NGT similarly led to a decrease in the
prevalence of microvascular disease-- an outcome that endured over time (which is after a
median follow-up period of 15 years) [46]. The regression of prediabetes along with the
restoration of normal glucose regulation (NGR) in the DPP/DPPOS cohort similarly produced a
decreased macrovascular risk amongst participants [44]. Researchers evaluating the Whitehall
study II cohort over time found that while the majority of subjects with HbA1c-defined
prediabetes either remained in a state of IGT or else progressed to type 2 diabetes over a fiveyear period, there was nonetheless a small subset (of the participant population) that experienced
a successful reversal from prediabetes to a state of normoglycemia [47]. While these alterations
may be due to random fluctuations occurring amongst certain participants, the reversion from 2h
PG-defined prediabetes back to a state of NGT was nonetheless beneficial in that it led to a
reduction in the risks that are associated with both the onset of heart disease and of CVD-related
mortality [47].
Addressing the onset of impaired glucose tolerance is necessary due to the limited
success associated with lifestyle interventions alone. Despite the emergence of certain benefits,
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these interventions (when undertaken alone) may be insufficient in terms of either reversing
prediabetes or else in delaying the onset of type 2 diabetes. By targeting important biomarkers,
addressing related glucoregulatory mechanisms, and evaluating alterations in adiposity,
metabolites, and in the lipid profile, the ensuing research findings can hopefully help to shed
light upon a host of variables responsible for inciting a reversal from a state of IGT back to one
of NGT [1]. With a greater understanding of the predictors involved in this regression, further
studies can hopefully aid in the creation of targeted and tailored interventions that can mitigate
dysglycemia by inducing a reversal backwards to a state of NGT.
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Chapter III
Methodology
3.1 Data Source and the Study Population
The data source utilized for the purpose of this secondary data analysis is the Insulin
Resistance Atherosclerosis Study (IRAS), which was a prospective cohort epidemiological study
that was a novelty due to the manner in which it examined a wealth of risk factors and their
subsequent associations with diabetes and insulin resistance syndrome 5[10]. The study began in
1992 with the approval of the Institutional Review Board (IRB) of Wake Forest University
School of Medicine [46]. The final sample consisted of a diverse population comprised of nonHispanic whites (n=614), African Americans (n=464), and Hispanics (n=548) to ensure
generalizable and all-encompassing results.
A total of 1625 participants aged between 40 to 69 years at baseline were recruited into
this longitudinal study in the time frame spanning from October of 1992 to April 1994. The
cohort was comprised of 719 male and 905 female participants, respectively. In order to ensure
metabolic diversity, researchers tried to recruit an equivalent number of individuals deemed to be
in a state of IGT, one of NGT, or else who were classified as being diabetic. Investigators
accomplished this by oversampling nondiabetics who either exhibited an elevated fasting plasma
glucose level or who were previously identified as being in a state of IGT. The baseline
measurements taken indicated that the majority of subjects had a normal glucose tolerance status
(44%), followed by a sizable portion of subjects who were either already diabetic (33%) or else
were categorized as being in a state of IGT (23%). Subjects were enlisted from four specific
clinical centers located in San Antonio, TX; Los Angeles, CA; San Luis Valley, CO; [and]
5

to merely name a few of the ensuing conditions.
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Oakland, CA. From 1997 to 1998, a follow-up examination was administered to the participants
approximately five years after the initial baseline examination (mean 5.2 years [range 4.6-6.6]),
which was accompanied by a high response rate of 81% [10]. This indicates that the majority of
the initial cohort remained, with only 19% of subjects being lost to follow-up. Each participant
gave his/her written informed consent, and the protocols were approved by local IRB committees
for both the baseline and follow-up examinations [10].
3.2 Screening and Eligibility, the Sample Selection Process, and Variable Measurement
The oral glucose tolerance test (OGTT) was utilized to measure baseline glucose
tolerance amongst participants, which is in direct accordance with the standards established by
the World Health Organization [47]. Participants underwent two separate visits to properly
obtain all of the required baseline information. With each visit lasting for approximately four
hours, the time interval between the two consecutive appointments spanned from one to thirty
days. Prior to the morning of the two visits, researchers asked that participants refrain from
alcohol consumption, avoid high intensity exercise, and that they also fast for 12 hours
beforehand [10]. The OGTT procedure is performed by taking an initial blood sample prior to
imbibing a liquid containing 75 grams of glucose.6 Blood was drawn again two hours after
consuming a solution needed to measure the remaining amount of glucose found in the system of
each respective subject. Insulin resistance was assessed by using the frequently sampled
intravenous glucose tolerance test (FSIGT) during the first and second visits [10]. In order to
ensure the accuracy of the insulin levels obtained amongst diabetics, subjects received an
injection of insulin as opposed to tolbutamide. Researchers did so this to acquire adequate plasma
insulin levels with greater ease given that some diabetics experienced either a blunted or an
6

This procedure is used to measure a subject’s fasting blood glucose level.
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absent insulin response to glucose [48]. Researchers also utilized a reduced sampling protocol by
requiring that only 12 plasma samples be collected as opposed to the 30 that are more frequently
used in this procedure [48]. Measuring insulin resistance was accomplished through the
administration of both regular human insulin (0.03 U/kg) and glucose in the form of a 50 %
solution (0.3 g/kg). These were injected every 20 minutes amongst subjects through an
intravenous line, with researchers inoculating participants with the glucose solution first [10]. 4
mL samples of blood were collected 12 separate times during a period of three hours through a
second intravenous line. These twelve respective samples were subsequently assayed in order to
measure the respective levels of plasma glucose and insulin concentrations. Participants fasted
for a period of twelve hours prior to their blood being drawn in order to measure their lipids,
fasting blood glucose levels, and the components of the biochemical profile more effectively.
Subjects filled out questionnaires regarding their self-reported conditions whereas
information pertaining to prevalent CVD and peripheral vascular disease was acquired through
the use of electrocardiographic and ultrasonographical methods. In addition to measuring blood
pressure, trained medical personnel evaluated subjects noninvasively in order to acquire their
respective anthropometric measurements. Body Mass Index (BMI) was calculated based on
weight measured in kilograms (kg) divided by height (in meters squared) for each of the
participants at baseline. During the first visit, F2-Isoprostanes were measured in urine samples
that were acquired and then stored at -70 degrees Celsius before being analyzed using liquid
chromatography [49]. Although a total of 901 urine samples were initially collected, researchers
only included 857 samples when attempting to measure the F2 – Isoprostanes concentration. The
concentration of F2 – Isoprostanes was evaluated through the use of liquid
chromatography/tandem mass spectrometry and the results were calibrated according to the
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urinary concentration of creatinine. More specifically, creatinine was assayed using a fast
electrospray ionization-tandem mass spectrometry method [49]. The inclusion of four different
F2 – Isoprostanes isomers was deliberate in order to measure them within the context of potential
fluctuations in BMI over time in an attempt to evaluate the influence that they may have (if any)
upon the potential for regression from a state of IGT back to one of NGT. The F2 – Isoprostanes
included were the following: iPF(2a)-ΙΙΙ, 2,3-dinor-iPF(2a)-ΙΙΙ, iPF(2a)-lV, along with 8,12-isoiPF(2a)-lV. The F2 -Isoprostanes index—the mean of the four aforementioned standardized F2Isoprostanes--was created based on the result for the four F2 – Isoprostanes isomers. This index
allowed for the ranking of participants to occur based upon a specific calculation, which is as
follows: [(X1i – M1)/SD1 +(X2i -M2)/SD2 +(X3i -M3)/SD3 +(X4i -M4)/SD4)/4]. In the context of this
formula, “i” is a code for a participant, X1-4 represent values indicative of the four F2 –
Isoprostanes isomers, M1-4 illustrates the mean of these four isomers, and SD1-4 stands for the
standard deviation values.
In order to ensure the accuracy of the results, participants were interviewed in their
preferred language [10]. The interview component of the two visits was comprised of questions
regarding whether or not each subject had any existing history related to previous instances of
myocardial infarction, stroke, coronary and/or carotid artery surgery, along with whether or not
he/she had endured peripheral vascular surgery [10]. Race/ethnicity was acquired through a selfreport manner, and nutrient intake data was both collected and assessed using a 114-item food
frequency interview instrument adapted by the National Cancer Institute (NCI) and subsequently
modified in order to account for both regional and ethnic food choices [50]. Information related
to alcohol consumption—both recent and average lifetime use—was similarly acquired with
questionnaires. Participants filled out surveys in order to obtain information regarding physical
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activity; responses were based on a one-year activity recall to improve feasibility and to
ultimately aid in their recollection of events [51]. In order to properly assess engagement in
physical activity, modifications were made to questions in an attempt to enhance the
responsiveness of subjects. This was accomplished by accounting for wide variety of activities
undertaken either at home, while at work, or even for leisurely purposes given that there was a
differential occurring between those living in urban environments relative to subjects residing in
rural areas instead [10].
3.3 The Definitions of “IGT” and “NGT” along with Their Respective Classifications
Since the purpose of this study was to evaluate those who were identified as being in a
state of IGT at baseline, this reduced the overall sample size from 1625 to only 303 subjects.
When measured amongst participants at baseline, IGT was defined as having a fasting glucose <
140 mg/dL and a 2-hr glucose ≥ 140 and <200 mg/dL when using the oral glucose tolerance test
(OGTT). In order to differentiate between the two states, those categorized as having NGT had
both a fasting and a 2-hr glucose level < 140 mg/dL, whereas those who were diagnosed as
diabetic instead were exhibiting fasting glucose levels of ≥ 140 mg/dL or 2-h glucose ≥
200mg/dL. By evaluating participants with IGT at baseline, there were only three possible
combinations (IGT to NGT, IGT to IGT, and IGT to T2D) from which to transition upon visit 2.7
However, this group of 303 participants was bifurcated into only two groups (as opposed
to the initial three combinations) upon which to make comparisons for simplicity. The first group
contains those who successfully reversed from a state of IGT back to one of NGT (n=81),
whereas the second group is comprised of subjects who did not successfully transition backwards

7

This led to a smaller cohort of only 303 individuals.
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to a state of NGT. By combining those who remained in a state of IGT along with participants
who transitioned from IGT to T2D, this led to the second group being composed of 222 subjects.
3.4 Analytical Cohort
The analytical cohort is comprised solely of participants categorized as being in a state of
IGT at baseline. Despite 370 participants having been initially classified as having IGT during
visit 1, only 303 individuals were ultimately included given that 65 participants were lost to
follow-up. Amongst the remaining 303 subjects, 81 individuals successfully reversed from a
state of IGT to one of NGT. The majority of participants (n=222) either remained in a state of
IGT during both visits or else had developed type 2 diabetes.
3.5 Statistical Analysis
This study utilizes exploratory data analysis (EDA) in the examination of the Insulin
Resistance Atherosclerosis (IRAS) cohort—a dataset initially comprised of 1624 participants.
The requisite analyses were performed using SAS software (version 9.4). Descriptive statistics
were computed for the entire baseline sample of the IRAS (n=1624) prior to analyzing those who
were classified as being in a state of IGT.8 While there were 370 individuals with IGT at
baseline, the final sample consisted of only 303 participants due to 65 subjects being classified as
“missing” upon follow-up.9 Evaluating statistical significance for the categorical variables across
both groups10 was acquired using the Wald Chi-square test. However, given the small sample
size (n=189) associated with measuring menopausal status during visits, Fisher’s exact test was
utilized instead to account for this stipulation.

8

This serves as a baseline against which to compare for those who had IGT at baseline relative
to the entire cohort.
9
after the requisite five-year time span had passed.
10
those who “reversed from IGT back to NGT” vs. subjects who had “no transition to NGT.”
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In order to properly evaluate the continuous variables, a univariate analysis was utilized
in SAS. Basic descriptive statistics such as the mean, median, the number of missing subjects,
and the interquartile range are provided. Tests for normality were run beforehand to ensure that
the continuous variables of interest could be properly analyzed with the Wilcoxon rank-sum test
along with the Kruskal-Wallis test prior to their inclusion. After passing an inspection to ensure
normality, every continuous variable was analyzed with a Wilcoxon rank-sum in order to
determine the presence of a significant difference (if any) that may have emerged between the
two separate groups. Analyzing differences between these two groups both at baseline and again
five years later (during the follow-up appointment) was accomplished. This was done in order to
determine if there were any significant differences emerging with respect to each variable (across
both groups) through the utilization of p-values generated in SAS. The results were found to be
of a statistically significant nature if the resulting p-value for a variable was less than 0.05. If the
opposite held true, then the results generated were not considered to be significantly different
across both groups of interest.
After making comparisons in which both the continuous and categorical variables were
evaluated independently across both groups for visits 1 and 2, we then tabulated the difference
occurring over time (or “delta”). The difference is equivalent to the results for visit 2 subtracted
from the outcomes found for visit 1. By measuring the delta and then calculating the p-value for
each variable of interest, this can help to determine whether or not the comparison of change was
in fact significantly different between those who transitioned from a state of IGT back to NGT
when compared to the subjects who did not. Analyzing the difference over time for each variable
was necessary in order to determine whether or not a statistically significant increase or decrease
was occurring when measured between these two groups. By looking at a wide array of
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variables, this study is a novelty due to its inclusion of as many factors as possible11 in order to
glean insight into a sector of diabetes research that so far has received limited attention.
For the purpose of this study, the continuous and categorical variables were organized
into seven respective tables and grouped according to key commonalities. For instance, Table I is
comprised of the demographic characteristics of participants with IGT at baseline and it
encompasses age, gender, race/ethnicity, and menopausal status. Table 2 consists of the baseline
anthropometric measures amongst participants with IGT at baseline and contains variables such
as weight, BMI, average waist circumference, and concludes with a waist/hip ratio measurement.
Table 3 encompasses the glucoregulatory characteristics of those with IGT at baseline, which
ultimately consists of variables such as FPG, 2-hr glucose, glucose effectiveness, insulin
sensitivity, AIR, fasting insulin, and 2-hr insulin. Table 4 is comprised of the baseline lipid
profile of participants in a state of IGT at baseline; the variables consist of total cholesterol,
triglycerides, HDL, and LDL levels, respectively. Table 5 contains the cardiovascular
characteristics of the participants with IGT at baseline, which involve blood pressure
measurements, variables pertaining to the carotid arteries, and the ankle/brachial index. Table 6
accounts for the baseline lifestyle characteristics of participants with IGT during visit one, and it
is comprised of several variables connected to variant levels of energy expenditure along
information related to with the self-reported smoking patterns of subjects. Lastly, table 7
encapsulates the remaining characteristics12 which consist of urinary biomarkers (such as
creatinine, albumin, and the four aforementioned F2-Isoprostanes). Through the incorporation of
as many variables as possible, this study attempts to motivate future work and further analyses

11
12

All of which are taken from the IRAS data set.
that did not fall into any of the aforementioned categories.
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within this area.13 By emphasizing the importance of prevention, expounding upon the
characteristics involved in the reversal from IGT back to a state of NGT is essential before it is
too late to effect change.

13

within the confines of the IRAS data set.
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Chapter IV
Results
4.1 Description of the Entire Study Sample
The study population was initially comprised of the entirety of the IRAS cohort—a total
of 1625 participants—when measured at baseline. 55.73% of subjects were female with 44.27%
of participants identifying as male. Non-Hispanic Whites accounted for the largest subgroup
(37.68%), followed by Hispanics (33.74%) and Non-Hispanic Blacks (28.57%) upon further
stratification. The cohort was primarily composed of subjects in the age range from 60 to 69
(37.65%), followed by those aged from 50 to 59 years old (34.20%) with only 28.16% of
subjects between 40 to 49 years of age. In terms of lifestyle habits and behaviors, most
participants had never smoked (43.67%), with a slightly smaller percentage indicating that they
had a former history of smoking but had since quit (39.65%). Current smokers (of which there
were 270) accounted for the smallest group (16.68%) when assessed by self-report. With respect
to hypertension, the majority had normal blood pressure readings (61.01%), with hypertensive
participants being in the minority (38.99%) at baseline. In terms of overall diabetes status, 718
participants exhibited normal glucose tolerance (NGT) levels when measured at baseline
(44.21%). In addition to those with NGT, 537 subjects were identified as having diabetes
(33.07%) with a subset of only 369 individuals categorized as being in a state of IGT (22.72%).
Moreover, with 41.62% of subjects having been classified as overweight and another 37.27%
found to be obese, only 21.09% of participants were classed as being within the normal weight
range.
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Table 1. Categorical Variables that are Baseline Characteristics for the Entire IRAS Cohort
Categorical Variables

N (missing values)

Percent

Gender
Males
Females
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Diabetes Status
Normal Glucose Tolerance (NGT)
Impaired Glucose Tolerance (IGT)
Diabetic
Hypertension
Yes (High)
No (Normal)
Smoking Status
Never Smoked
Former Smoker
Current Smoker
Weight Categorization
Normal
Overweight
Obese

1624 (0)
719
905
1624 (0)
612
464
548
1624 (0)
718
369
537
1616 (8)
630
986
1619 (5)
707
642
270
1617 (7)
341
673
603

100
44.27
55.73
100
37.68
28.57
33.74
100
44.21
22.72
33.07
100
38.99
61.01
100
43.67
39.65
16.68
100
21.09
41.62
37.29
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Table 2. Continuous Variables that are Baseline Characteristics for the Entire IRAS Cohort
Continuous Variables

N (missing values)

Mean (SD)

Age (measured in years)
Fasting Glucose (mg/dl)
BMI (kg/m2)
2-hour Glucose (mg/dl)
Triglycerides (mg/dl)
Fasting Insulin (uU/ml)
HDL (mg/dl)

1624 (0)
1623 (1)
1617 (7)
1612 (12)
1615 (9)
1620 (4)
1615 (9)
627 (997)

55.647 (8.469)
123.269 (49.53)
29.47 (5.978)
186.52 (104.567)
152.17 (120.33)
18.37 (15.52)
45.040 (14.609)
0.030 (0.845)

8,12-iso-iPF(2a)-lV (ng/mg CN)
iPF(2a)-lV (ng/mg CN)
2,3-dinor-iPF(2a)-ΙΙΙ (ng/mg CN)
iPF(2a)-ΙΙΙ (ng/mg CN)
Insulin sensitivity
(SI, x10-4minutes-1/µUml)
Acute Insulin Response
(microU/ml)
Urine Creatinine (mg/dL)
Urine Albumin (mg/L)
LDL (mg/dl)
AIR (mean of 2,4 min ins)

627 (997)
627 (997)
627 (997)
627 (997)
1482 (142)

4.25 (2.938)
6.539 (4.1265)
4.55 (3.223)
0.251 (0.197)
1.645 (1.892)

1560 (64)

345.358 (455.081)

1587 (37)
1592 (32)
1560 (64)
1535 (89)

133.743 (80.81)
22.955 (65.35)
141.224 (35.216)
53.152 (51.308)

Total Energy Expended
(kcal/kg/yr) for Visit I

1596 (28)

14573.62 (2641.46)

High Energy Expended (kcal/kg/yr)
for Visit I

1603 (21)

1173.07 (2381.38)

Moderate Energy Expended
(kcal/kg/yr) for Visit I

1600 (24)

2642.40 (2454.00)

F2 -IsoP Index1

Note: The Index is the mean of four standardized F2-Isoprostanes
4.2 Prevalence of participants with IGT when measured at Baseline
As shown in Table 1, 369 individuals were identified as being in a state of IGT at
baseline (22.72%). Due to attrition occurring over the five-year time frame, only 303 of those
with IGT at baseline remained.14 At follow-up, the participants were bifurcated into two
respective categories, the first of which consists of those who reversed from a state of IGT to one

14

given that 66 subjects were counted as missing during visit 2.
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of NGT (n=81). The second group contains subjects who remained prediabetic (i.e., IGT) during
both visits (n=121) along with those who fully transitioned from a state of IGT to overt diabetes
(n=101) which total to 222 when combined.
4.3 The Characteristics of Participants with IGT at Baseline and the Potential for Reversal
In table 3, sex (p=0.0438) and menopausal status (p=0.0350) were statistically
significant, whereas this was not the case for ethnicity and age during visit 1. Amongst those
who successfully regressed from a state of IGT back to NGT (n=81), 46.91% were male
participants accompanied by a slightly higher composition of female subjects (53.09%). In table
4, subjects with a lower average waist circumference (mean of 91.70) were more likely to
reverse from a state of IGT backwards to one of NGT; participants who failed to transition were
more likely to have a higher average waist circumference (mean=96.07) (p=0.0061).
Additionally, those with lower BMIs (mean=28.84) experienced a higher rate of regressing from
a prediabetic state back to NGT relative to their peers with higher average BMIs (mean=31.10)
(p=0.0056). Lastly, no statistically significant differences emerged across groups with respect to
the waist/hip ratio (p=0.1324), weight (p=0.0853) and height (p=0.1003) in table 4.
As illustrated in table 5, those with a lower fasting insulin level (mean=15.43) at baseline
were significantly more likely to reverse from a state of IGT back to NGT when compared to
subjects who did not (mean=20.85) (p=0.0029). Moreover, individuals with greater levels of
insulin sensitivity (mean=1.79) were significantly more likely to regress from IGT to NGT when
compared to those with lower levels of insulin sensitivity (mean=1.10) (p=0.0035). Participants
with a lower amount of fasting glucose (mean=100.73) were also more likely to experience a
successful reversal of prediabetes relative to subjects who had higher fasting glucose levels
(mean=106.11) (p=0.0003). Those with a greater acute insulin response (AIR) (mean=478.89)
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were more likely to reverse from IGT to NGT when compared to those with a lessened AIR
(mean=313.79) when calculated with the mathematical minimal model (p=0.0026). Participants
exhibiting lower levels of 2-hr glucose (mean=155.38) were also more likely to experience a
successful reversal back to a state of NGT relative to those who had higher levels of 2-hr glucose
(mean=106.11) (p<.0001).
In table 6, participants exhibiting a greater HDL level (mean=48.67) were significantly
more likely to transition backwards from a state of IGT to one of NGT when compared to those
with a lower HDL level (mean=43.82) (p=0.0061). Subjects with higher levels of triglycerides
(mean=163.08) were less likely to successfully return to NGT from a prediabetic state relative to
participants with lower triglyceride levels (mean=131.52) (p<0.0001). However, other variables
from which the baseline lipid profile is comprised did not generate significant findings between
the two groups, such as total cholesterol (p=0.3559) and LDL levels (p=0.5428). As shown in
table 7, there were no statistically significant links between cardiovascular characteristics and a
subsequent transition from a state of IGT to NGT.
As showcased in table 8, there were no statistically significant outcomes occurring
between baseline lifestyle characteristics--the types of energy expenditure and smoking status-and an eventual transition from a state of IGT to NGT. As delineated in table 9, the four F2Isoprostanes along with urine creatinine and urine albumin did not produce any statistically
significant differences between groups.
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Table 3: Demographic Characteristics of Participants with IGT at Baseline
Participant
Characteristics*
Sex
Male N (%)
Female N (%)
Missing N (%)
Ethnicity
Non-Hispanic White
N (%)
Non-Hispanic Black
N (%)
Hispanic N (%)
Missing N (%)
Menopausal Status
(At visit 1)
Pre- N (%)
Peri- N (%)
Post- N (%)
Age (in years)
(At visit 1)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value

38 (46.91%)
43 (53.09%)
0

76 (34.23%)
146 (65.77%)
0

*0.0438

27 (33.33%)

90 (40.54%)

0.3575

27 (33.33%)

57 (25.68%)

27 (33.33%)
0

75 (33.78%)
0

11 (25.58%)
2 (4.65%)
30 (69.77%)

15 (10.27%)
11 (7.53%)
120 (82.19%)

*0.0350

56.75 (8.75)
58.00 (15.00)
0

56.47 (7.69)
57.00 (13.00)
0

0.6357

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; Fisher’s Exact Test was used to analyze Menopausal Status due to its
small sample size (n=189) whereas the Wald chi-square test was utilized for the remaining
categorical variables. These are stratified above with the respective N and % provided for each of
the levels.
Table 4: Baseline Anthropometric Measures in Participants with IGT (at Visit 1)
Participant
Characteristics*
Average Waist
Circumference
(At visit 1)
Mean (SD)
Median (IQR)
Missing
BMI (kg/m2)
(At visit 1)
Mean (SD)
Median (IQR)

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value

91.70 (15.72)
89.00 (81.50, 98.20)
0

96.07 (12.84)
95.15 (87.00, 102.35)
1

*0.0061

28.84 (5.96)
27.68 (25.39, 31.05)

31.10 (6.60)
29.53 (26.41, 34.72)

*0.0056
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Missing

Waist/Hip Ratio
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Weight (in Kg.)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Height (in cm.)
(At visit 1)
Mean (SD)
Median (IQR)
Missing

0

0

0.86 (0.10)
0.85 (0.76, 0.94)
0

0.88 (0.08)
0.87 (0.81, 0.94)
1

0.1324

81.39 (18.96)
78.09 (67.00, 93.50)
0

85.13 (18.55)
82.50 (73.55, 93.80)
0

0.0853

167.77 (9.36)
166.30 (161.40, 175.00)
0

165.57 (9.36)
164.50 (158.80, 173.00)
0

0.1003

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
Table 5: Glucoregulatory Characteristics of Participants with IGT at Visit 1
Participant
Characteristics*
Fasting Insulin
(uU/mL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
2 Hr Insulin (uU/mL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Si value
(At visit 1)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value

15.43 (10.41)
12.00 (8.00, 21.00)
0

20.85 (23.84)
16.00 (12.00, 23.00)
0

*0.0029

130.81 (126.47)
98.00 (69.00, 155.00)
0

137.51 (102.56)
110.50 (77.00, 165.00)
0

0.1712

1.79 (1.70)
1.33 (0.79, 2.22)
4

1.10 (0.84)
1.00 (0.48, 1.56)
19

*0.0035
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Sg value
(At visit 1)
Mean (SD)
Median (IQR)
Missing
AIR from MINMOD
(At visit 1)
Mean (SD)
Median (IQR)
Missing
2 Hr Glucose (mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Fasting Glucose
(mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing

0.02 (0.01)
0.02 (0.01, 0.02)
4

0.02 (0.01)
0.02 (0.01, 0.02)
19

*0.0617

478.89 (465.01)
344.73 (149.45, 625.45)
2

313.79 (332.70)
215.00 (77.96, 444.68)
6

*0.0026

155.38 (14.08)
151.00 (145.00, 162.00)
0

166.23 (17.40)
165.00 (151.00, 181.00)
0

*<.0001

100.73 (10.63)
100.00 (94.00, 107.00)
0

106.11 (10.78)
106.00 (98.00, 113.00)
0

*0.0003

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
Table 6: Baseline Lipid Profile of Participants with IGT (at Visit 1)
Participant
Characteristics*
Tot Chol (mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
HDL (mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
LDL (mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value

211.53 (37.73)
206.00 (183.00, 237.00)
2

216.08 (37.77)
211.50 (185.50, 239.00)
2

0.3559

48.67 (15.31)
45.00 (39.00, 59.00)
2

43.82 (14.08)
41.00 (35.00, 50.00)
1

*0.0061

141.85 (37.08)
140.00 (115.50, 166.00)
5

144.35 (34.73)
144.00 (120.00, 164.00)
11

0.5428

42

Trigs (mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing

131.52 (99.80)
104.00 (75.00, 159.00)
2

163.08 (88.19)
140.00 (99.00, 197.00)
1

*<.0001

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
Table 7: Cardiovascular Characteristics of Participants with IGT (at Visit 1)
Participant
Characteristics**
Hypertension
(At visit 1)
High N (%)
Normal N (%)
Missing N (%)
Ankle/Brachial Index
(at visit 1)
Mean (SD)
Median (IQR)
Missing
Mean Internal Carotid
Artery Far Wall Max.
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Mean Common
Carotid Artery Far
Wall Max.
(At visit 1)
Mean (SD)
Median (IQR)
Missing
SYS1V1 Systolic
(Baseline) Visit 1 (Ave
2&3)
Mean (SD)
Median (IQR)
Missing
DIAS1V1 Diastolic
(Baseline) Visit 1 (Ave
2&3)
Mean (SD)
Median (IQR)

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value*

30 (37.04%)
51 (62.96%)
0

93 (41.89%)
129 (58.11%)
0

0.4463

1.21 (0.09)
1.21 (1.14, 1.28)
0

1.19 (0.12)
1.20 (1.12, 1.26)
0

0.3355

0.91 (0.32)
0.81 (0.75, 0.94)
8

0.93 (0.42)
0.79 (0.71, 1.01)
29

0.3480

0.85 (0.23)
0.81 (0.70, 0.93)
6

0.82 (0.17)
0.80 (0.70, 0.89)
23

0.6044

124.00 (18.23)
123.00 (111.00, 135.00)
0

125.58 (17.33)
124.00 (114.00, 135.00)
0

0.4623

78.26 (8.87)
79.00 (70.00, 85.00)

77.69 (9.07)
78.00 (71.00, 83.00)

0.6591
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Missing

0

0

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; the Wald chi square test was utilized for the remaining categorical
variables.
Table 8: Baseline Lifestyle Characteristics of Participants with IGT (at Visit 1)
Participant
Characteristics*
Smoking Status
(At visit 1)
Never- N (%)
Ex- N (%)
Current- N (%)
Missing N (%)
Total Energy
Expended (kcal/kg/yr)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
High Energy Expended
(kcal/kg/yr)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Mod. Energy
Expended (kcal/kg/yr)
(At visit 1)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value

38 (46.91 %)
30 (37.04 %)
13 (16.05 %)
0

107 (48.20 %)
88 (39.64 %)
27 (12.16 %)
0

0.6693

14226.56 (2030.44)
13626.00 (12967.25,
14717.25)
0

14367.56 (2517.73)
13765.94 (12756.00,
15232.00)
4

0.9598

902.07 (1449.33)
288.00 (0.00, 1152.00)
0

1011.03 (2145.40)
234.00 (0.00, 1152.00)
4

0.4003

2452.00 (2110.69)
1772.00 (984.0, 3162.0)
0

2514.57 (2158.55)
1816.00 (878.0, 3648.0)
3

0.8023

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical
variables.
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Table 9: Urinary Biomarkers amongst Participants at Baseline
Participant
Characteristics*
Urine Creatinine
(mg/dL)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
Urine Albumin (mg/L)
(At visit 1)
Mean (SD)
Median (IQR)
Missing
mean of 4 standardized
F2-isoPs.
Mean (SD)
Median (IQR)
Missing
iPF_2a
Mean (SD)
Median (IQR)
Missing
dinor_ng_mg_cn
Mean (SD)
Median (IQR)
Missing
ipf2_ng_mg_cn
Mean (SD)
Median (IQR)
Missing
iso_iPF_2a
Mean (SD)
Median (IQR)
Missing
(Mean of 4
standardized F2isoPs/BMI) *(1000)
Mean (SD)
Median (IQR)
Missing
(IPF_2a/BMI) *(1000)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT upon Follow-Up
(N=81)

No Transition to NGT
at Follow-Up
(N= 222)

P-Value

149.94 (97.67)
127.05 (90.30, 186.90)
1

139.21 (77.02)
131.25 (79.80,180.60)
4

0.7564

13.00 (21.80)
6.20 (6.20, 8.15)
1

17.21 (52.39)
6.20 (6.20, 10.60)
5

0.7151

0.0 (0.63)
-0.18 (-0.53, 0.40)
23

0.08 (0.85)
-0.15 (-0.50, 0.48)
41

0.9730

0.24 (0.15)
0.20 (0.13, 0.29)
23

0.24 (0.16)
0.21 (0.13, 0.29)
41

0.9843

4.55 (2.29)
3.99 (2.93, 5.37)
23

4.95 (3.20)
4.17 (2.83, 6.22)
41

0.8162

6.37 (3.56)
5.56 (3.71, 8.32)
23

6.87 (4.79)
5.28 (3.69, 8.61)
41

0.9695

4.31 (2.64)
3.78 (2.37, 5.35)
23

4.34 (2.92)
3.59 (2.50, 5.43)
41

0.9010

7.77(4.60)
6.96 (3.95, 10.19)
23

7.64 (4.92)
6.45 (3.99, 9.78)
41

0.7417

210.21 (120.64)
178.00 (124.23, 259.38)
23

216.52 (147.26)
168.69 (118.93, 275.80)
41

0.7368
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(Dinor_ng_mg_cn/BMI)
*(1000)
Mean (SD)
Median (IQR)
Missing
(ipf2_ng_mg_cn/BMI)
*(1000)
Mean (SD)
Median (IQR)
Missing
(Iso_iPF_2a/BMI)
*(1000)
Mean (SD)
Median (IQR)
Missing

139.24 (76.68)
118.91 (88.29, 179.55)
23

136.59 (87.67)
116.63 (75.98, 172.65)
41

0.5311

147.28 (66.87)
136.25 (103.86, 181.44)
23

155.08 (97.83)
137.94 (84.66, 196.73)
41

0.8820

-1.00 (19.65)
-5.74 ( -17.52, 14.86)
23

1.61 (24.89)
-4.26 (-15.73, 12.48)
41

0.8623

*All continuous variables are reported with the mean, standard deviation, median, along with the
IQR, which is the 75th-25th percentile contrast.
**Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
4.4 Results found for Participants with IGT at Baseline when Examined during Follow-up
In table 10, menopausal status produced a statistically significant result in which female
subjects who either pre-menopausal (n=7, 16.28%) or else peri-menopausal (n=3, 6.98%) were
more likely to successfully reverse from IGT back to a state of NGT (p=0.0089). Amongst those
who did not transition backwards, 93.15% of the women in that group (n=136) identified as
being post-menopausal upon follow up; this percentage is far higher than the 76.74% of postmenopausal women who did successfully revert from a state of IGT (n=33) back to one of NGT.
While this reinforces previous results found with respect to the statistically significant influence
of gender, age did not elicit a statistically significant result (p=0.6080).
Subjects with a lower average waist circumference (mean= 93.61) as shown in table 11
were more likely to reverse from prediabetes to a state of NGT; those who did not had higher
average waist circumferences (mean=98.39) overall (p=0.0031). Subjects with lower BMIs at
follow-up (mean=29.22) were more successful in reversing from a state of IGT to one of NGT.
In contrast, subjects with higher BMIs (mean=31.79) were less likely to successfully transition
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backwards (p=0.0011). No statistically significant differences emerged for the waist/hip ratio
(p=0.1081) or else for the weight variable (p=0.0562) when measured at follow-up.
In table 12, subjects with a lower fasting insulin (mean=18.23) were significantly more
likely to reverse from a state of IGT back to one of NGT in comparison to those with higher
fasting insulin measurements (mean=23.83) at follow-up (p=0.0006). Similarly, participants with
lower 2-hr insulin levels (mean=117.45) at follow-up had more success in regressing from a
prediabetic state back to one of NGT relative to those with higher 2-hr insulin levels
(mean=167.62) given that the latter had far more difficulty achieving this reversal (p<0.0001).
Additionally, individuals with greater levels of insulin sensitivity (mean=1.47) were also
significantly more likely to reverse from a state of IGT to one of NGT in comparison to those
with decreased insulin sensitivity (mean=0.80) overall (p<0.0001). Subjects with a lower amount
of fasting glucose (mean=98.39) were also more likely to experience a successful reversal of
prediabetes relative to their peers who exhibited higher fasting glucose levels (mean=121.53) at
follow-up (p<0.0001). Participants with a greater acute insulin response (AIR) (mean=648.09)
were more likely to reverse from a state of IGT to one of NGT in comparison to those with a
lesser AIR (mean=263.46) during visit 2 (p<0.0001).15 In terms of 2-hr glucose, subjects with
higher levels (mean=212.15) were less likely to transition backwards from a state of IGT to NGT
when compared to participants who exhibited lower levels of 2-hr glucose (mean=119.76) at
follow-up (p<0.0001).
Table 13 indicates that the subjects with greater HDL levels (mean=50.58) were
significantly more likely to transition from a state of IGT to one of NGT relative to those with
lower HDL levels (mean=45.19) at follow-up (p=0.0153). Participants with higher levels of

15

when calculated utilizing the mathematical minimal model.
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triglycerides (mean=155.64) were less likely to successfully regress to NGT from a prediabetic
state when compared to those with lower triglyceride levels (mean=116.93) (p<0.0001). The
inclusion and analyses of the ratios of the four F2-Isoprostanes16 did not produce any significant
results. Moreover, no significant findings emerged for total cholesterol (p=0.0706) or for LDL
levels (p=0.1339) when both variables were measured during the follow-up visit.
In table 14, no statistically significant findings emerged with regard to cardiovascular
characteristics and the potential for a reversal from prediabetes to a state of NGT. The same held
true for lifestyle characteristics in that no statistically significant findings arose for the three
types of energy expenditure or for smoking status (which is displayed in table 15). As shown in
table 16, both urine creatinine (p=0.3162) and urine albumin (p=0.7782) failed to generate
statistically significant findings with respect to regressing from a state of prediabetes back to one
of NGT.
Table 10. Demographic and Baseline Characteristics by Glucose Tolerance Status (at Visit 2)
Participant
Characteristics

Reversal from IGT
to NGT (N=81)

No Transition to
NGT
(N= 222)

P-Value

Menopausal Status*
(At visit 2)
Pre- N (%)
Peri- N (%)
Post- N (%)
Missing N (%)

7 (16.28%)
3 (6.98%)
33 (76.74%)
0

7 (4.79%)
3 (2.05%)
136 (93.15%)
0

*0.0089

Age (in years)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

62.09 (8.72)
64.00 (15.00)
0

61.71 (7.81)
62.00 (13.00)
0

0.6080

*As a categorical variable, Menopausal Status required the utilization of Fisher’s Exact test
in order for the p-value to appropriately account for the small sample size (n=189). This
variable is stratified above with the N and % provided for each level.
16

when each of the F2-Isoprostanes are divided by the BMI acquired for visit 2.
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•

All continuous variables are reported with the mean, standard deviation, median, along
with the IQR, which is the 75th-25th percentile contrast.

Table 11: Anthropometric Measures in Participants with IGT (at Follow-Up)
Participant
Characteristics*
Average Waist
Circumference
(At visit 2)
Mean (SD)
Median (IQR)
Missing
BMI (kg/m2)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Waist/Hip Ratio
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Weight (in Kg.)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Height (in cm.)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

•

Reversal from IGT to
NGT (N=81)

No Transition to NGT
(N= 222)

P-Value

93.61 (15.63)
91.35 (17.35)
3

98.39 (13.70)
96.80 (14.50)
0

*0.0031

29.22 (6.83)
27.97 (5.93)
4

31.79 (7.08)
29.86 (8.62)
1

*0.0011

0.87 (0.13)
0.85 (0.79, 0.94)
3

0.88 (0.08)
0.88 (0.82, 0.94)
0

0.1081

82.78 (21.60)
79.09 (68.20, 91.36)
4

86.52 (19.43)
83.30 (73.50, 97.32)
1

0.0562

168.05 (9.16)
166.40 (160.70,
175.10)
4

165.20 (9.58)
164.35 (158.20,
172.70)
0

*0.0323

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon
Rank Sum/Kruskal Wallis Test.
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Table 12: Glucoregulatory Characteristics of Participants with IGT at Follow-Up
Participant
Characteristics*
Fasting Insulin
(uU/mL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
2 Hr Insulin
(uU/mL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Si value
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Sg value
(At visit 2)
Mean (SD)
Median (IQR)
Missing
AIR from
MINMOD
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Fasting Glucose
(mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
2 Hr Glucose
(mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT (N=81)

No Transition to
NGT (N= 222)

P-Value

18.23 (9.82)
15.00 (12.00, 21.00)
0

23.83 (14.85)
20.50 (14.00, 30.00)
2

* 0.0006

117.45 (123.42)
14.00 (62.00, 129.00)
3

167.62 (148.76)
126.00 (89.50, 182.00)
6

*<.0001

1.47 (1.56)
1.13 (0.55, 1.67)
13

0.80 (1.58)
0.52 (0.00, 1.02)
33

*<.0001

0.02 (0.01)
0.02 (0.01, 0.02)
13

0.02 (0.01)
0.02 (0.01, 0.02)
34

*0.0020

648.09 (749.28)
376.14 (186.14, 718.36)
13

263.46 (316.56)
196.91 (38.55, 383.18)
36

*<.0001

98.39 (11.75)
98.00 (91.50, 107.00)
0

121.53 (37.91)
110.50 (99.50, 131.00)
3

*<.0001

119.76 (15.52)
122.00 (110.50, 132.50)
2

212.15 (69.23)
192.00 (167.00,
237.00)
4

*<.0001

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
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Table 13: Baseline Lipid Profile of Participants with IGT (at Visit 2)
Participant
Characteristics*

Reversal from IGT to
NGT (N=81)

No Transition to
NGT
(N= 222)

P-Value

Tot Chol (mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

203.71 (44.65)
201.00 (174.50, 226.50)
5

211.45 (36.62)
208.50 (188.00,
232.00)
6

0.0706

HDL (mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

50.58 (16.85)
47.00 (39.00, 59.00)
5

45.19 (13.40)
43.50 (36.00,
52.50)
6

* 0.0153

LDL (mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

129.76 (42.51)
127.00 (103.50, 147.00)
5

135.11 (33.87)
131.50 (113.00,
154.00)
6

0.1339

Trigs (mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

116.93 (71.39)
93.00 (71.00, 141.00)
5

155.64 (75.49)
141.00 (99.00,
190.50)
6

*<.0001

Ratio of
(iPF_2a)/BMI_2
(At visit 2)
Mean (SD)
Median (IQR)
Missing

0.01 (0.00)
0.01 (0.00, 0.02)
25

0.01 (0.00)
0.01 (0.00, 0.02)
42

0.7367

0.21 (0.13)
0.18 (0.13, 0.26)
25

0.21 (0.15)
0.16 (0.11, 0.28)
42

0.7537

0.13 (0.07)
0.12 (0.09, 0.17)
25

0.13 (0.09)
0.12 (0.07, 0.17)
42

0.6670

Ratio of
(ipf2_ng_mg_cn)/B
MI_2
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Ratio of
(Iso_iPF_2a)/BMI_2
(At visit 2)
Mean (SD)
Median (IQR)
Missing
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Ratio of
(Dinor_ng_mg_cn)/
BMI_2
(At visit 2)
Mean (SD)
Median (IQR)
Missing

0.15 (0.07)
0.13 (0.10, 0.19)
25

0.15 (0.10)
0.13 (0.09, 0.19)
42

0.8842

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
Table 14: Cardiovascular Characteristics of Participants with IGT (at Visit 2)
Participant
Characteristics*
Hypertension
(At visit 2)
High N (%)
Normal N (%)
Missing N (%)
Ankle/Brachial
Index (at visit 2)
Mean (SD)
Median (IQR)
Missing
Mean Internal
Carotid Artery
Far Wall Max.
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Mean Common
Carotid Artery
Far Wall Max.
(At visit 2)
Mean (SD)
Median (IQR)
Missing
SYS2V2 Systolic
(Baseline) (Ave
2&3)
(At visit 2)
Mean (SD)

Reversal from IGT
to NGT (N=81)

No Transition to NGT
(N= 222)

P-Value

35 (43.75%)
45 (56.25%)
1 (0.012%)

123 (55.56%)
98 (44.34%)
1 (0.004%)

0.0974

1.12 (0.13)
1.13 (1.05, 1.20)
3

1.12 (0.14)
1.14 (1.07, 1.20)
1

0.9205

1.04 (0.48)
0.84 (0.40)
6

1.03 (0.61)
0.86 (0.36)
8

0.4065

0.85 (0.24)
0.80 (0.23)
3

0.87 (0.21)
0.82 (0.24)
4

0.1860

126.92 (18.91)
125.00 (116.00,

129.24 (16.95)
127.00 (118.00,

0.2064

52

Median (IQR)
Missing

DIAS1V1
Diastolic
(Baseline) (Ave
2&3)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

136.00)
6

140.00)
14

77.59 (9.95)
79.00 (70.00, 84.00)
6

78.52 (10.04)
78.00 (71.00, 84.00)
14

0.5965

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical
variables. The categorical variable is stratified above with the respective N and % provided for
each level.
Table 15: Lifestyle Characteristics of Participants with IGT at Follow-Up
Participant
Characteristics*
Smoking Status
(At visit 2)
Never- N (%)
Ex- N (%)
Current- N (%)
Missing N (%)
Mod. Energy
Expended
(kcal/kg/yr)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
Total Energy
Expended
(kcal/kg/yr)
(At visit 2)
Mean (SD)
Median (IQR)
Missing
High Energy
Expended
(kcal/kg/yr)
(At visit 2)

Reversal from IGT
to NGT (N=81)

No Transition to
NGT (N= 222)

P-Value

38 (46.91%)
33 (40.74%)
10 (12.35%)
0

107 (48.63 %)
96 (43.63 %)
17 (7.70 %)
2 (0.009%)

0.4584

2148.63 (2498.00)
1582.00 (1496.00)
2

2268.92 (2343.88)
1520.00 (2350.00)
3

0.5956

14011.05 (2458.92)
13181.25 (1536.63)
2

14213.19 (2794.36)
13538.63 (2337.38)
3

0.5283

860.35 (2000.92)
160.00 (864.00)

1019.36 (2465.68)
168.00 (1072.00)

0.9113
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Mean (SD)
Median (IQR)
Missing

2

3

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical
variables. “Smoking status” is stratified above with the respective N and % provided for each
level.
Table 16: Urinary Biomarkers amongst Participants at Follow-Up
Participant
Characteristics**
Urine Creatinine
(mg/dL)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

Reversal from IGT to
NGT (N=81)

No Transition to NGT
(N= 222)

P-Value*

125.38 (64.85)
116.00 (77.00, 160.00)
2

134.61 (75.41)
125.00 (86.00, 160.00)
3

0.3162

Urine Albumin (mg/L)
(At visit 2)
Mean (SD)
Median (IQR)
Missing

14.61 (18.00)
6.10 (5.80, 13.30)
2

54.79 (391.95)
6.00 (5.80, 13.20)
3

0.7782

(Mean of 4
standardized F2isoPs/BMI for visit 2)
*(1000)
Mean (SD)
Median (IQR)
Missing

7.73 (4.72)
7.00 (4.00, 10.50)
25

7.53 (4.89)
6.17 (3.90, 9.72)
42

0.7367

(IPF_2a/BMI for visit
2) *(1000)
Mean (SD)
Median (IQR)
Missing

208.74 (129.78)
175.60 (127.66, 255.43)
25

213.17 (146.22)
164.42 (112.29, 282.93)
42

0.7357

134.57 (87.22)
115.64 (73.83, 165.65)
42

0.6670

(Dinor_ng_mg_cn/BMI
for visit 2) *(1000)
Mean (SD)
133.80 (73.95)
Median (IQR)
118.48 (88.12, 170.93)
Missing
25
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(ipf2_ng_mg_cn/BMI
for visit 2) *(1000)
Mean (SD)
Median (IQR)
Missing

145.77 (71.46)
132.80 (97.81, 185.21)
25

153.16 (100.28)
127.28 (87.55, 190.33)
42

0.8842

(Iso_iPF_2a/BMI for
visit 2) *(1000)
Mean (SD)
Median (IQR)
Missing

-1.69 (19.62)
-8.51 (-16.98, 14.36)
25

1.79 (24.66)
-3.86 (-15.87, 12.42)
42

0.6101

*All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
**Differences between groups for continuous variables were assessed using the Wilcoxon
Rank Sum/Kruskal Wallis Test.
4.5 The Comparison of Change in Characteristics (between visits 1 & 2) between the
Groups of Participants who had IGT at Baseline.
In table 17, menopausal status (p=0.0365) was statistically significant in terms of the
comparison of change across both groups over time. 13.95 percent of women who reversed from
IGT to a state of NGT were pre-menopausal both at baseline and again upon follow-up, which is
higher relative to those who never transitioned backwards. 82.19% of women who never
successfully reversed were post-menopausal during both visits, which is a higher percentage
compared to the mere 67.44% of subjects who did successfully regress from IGT to NGT.
Changes in age between the two visits bore no statistically significant impact upon the outcome
of interest (p=0.1759). In table 18, the comparison of change between groups for BMI was
statistically significant (p=0.0348). This indicates that participants who did not successfully
reverse to a state of NGT had a larger increase in mean BMI over time (mean=+0.76 kg/m2)
relative to the changes in BMI amongst subjects who did successfully transition from a state of
IGT to NGT (mean=+0.34 kg/m2). However, there were no statistically significant differences
occurring with respect to changes in the waist/hip ratio, weight, and average waist
circumference.
55

In table 19, subjects who reversed from a state of IGT to NGT experienced a decrease in
2-hr insulin between visits 1 and 2 (mean= -15.97) whereas those who failed to transition had an
increase in 2-hr insulin levels (mean=30.34) over time (p=0.0032). Subjects who successfully
reversed from IGT to NGT similarly had a decrease in 2-hr glucose levels (mean= -35.81)
whereas those who did not regress encountered higher 2-hr glucose levels (mean=45.94) over
time (p<0.0001) A similar pattern arose with fasting glucose in that those who regressed from
IGT to NGT had a decrease between visits 1 and 2 (mean=2.34) whereas subjects who did not
transition backwards from IGT had an overall increase in their respective levels (mean=15.48)
over time (p<0.0001). Participants who encountered an increase in overall acute insulin response
(AIR) (mean=192.23) between the two visits were more likely to reverse from a state of IGT to
NGT relative to their peers who experienced a decrease in AIR (mean= -59.52) over time17
(p=0.0007). However, the comparison of change for fasting insulin (p=0.1291), insulin
sensitivity (p=0.1723), and glucose effectiveness (p=0.6576) were not significantly different
between those who transitioned from a state of IGT to NGT relative to subjects who did not.
As shown in table 20, no statistically significant findings occurred when comparing the
change over time for characteristics that comprise the lipid profile. In table 21, subjects who
reversed from IGT to NGT had a lower average Common Carotid Artery18 (CCA) value
(mean=0.00) relative to those who did not transition backwards from IGT (mean=0.05). The
subjects who failed to regress to NGT experienced an increase in their mean CCA values over
time between visits (p=0.0369). There were no significant findings emerging for HDL, LDL,
total cholesterol, and triglyceride levels. Similarly, no significant differences arose with regard to
the F2-isoprostane ratios when measured over the five-year time frame. In table 22, no
17
18

with the mathematical minimal model.
The Mean CCA is with regard to the far wall max.
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statistically significant changes emerged for lifestyle characteristics when measured for both
groups between visits 1 and 2. In table 23, no statistically significant changes occurred for urine
albumin (p=0.6372) or for urine creatinine (p= 0.3887) when both biomarkers were evaluated
over time.
Table 17: The Change in Demographic Characteristics between Visits 1 & 2 amongst
Participants with IGT at Baseline
Characteristics

Menopausal Status
(N=189) *
Pre – Pre-N (%)
Pre – Peri N (%)
Pre – Post N (%)
Peri– Peri N (%)
Peri– Post N (%)
Post– Peri N (%)
Post – Post N (%)
Missing N (%)

Reversal from
IGT to NGT

Did not
Reverse to
NGT

P-value
(For
comparison
of change
between the
groups)

6 (13.95%)
3 (6.98 %)
2 (4.65%)
0 (0.00%)
2 (4.65%)
0 (0.00%)
29 (67.44%)
1 (2.33%)

6 (4.11%)
2 (1.37%)
7 (4.79%)
1 (0.68%)
9 (6.16%)
0 (0.00%)
120 (82.19%)
1 (0.68%)

*0.0365

*Fisher’s Exact test was utilized for the categorical variables of interest due to the small sample
size affiliated with menopausal status. The categorical variable is stratified above with the
respective N and % provided for each level.
Table 18: The Change in Anthropometric Measures between Visits 1 & 2 amongst Participants
with IGT at Baseline
Characteristics*

BMI (kg/m2)
Mean (SD)
Median (IQR)
Missing

Reversal from
IGT to NGT
(N=81)

No Transition
to NGT
(N=222)

P-Value
(For the
comparison
of change
between the
groups)

0.34 (2.24)
0.11 (-1.03, 1.24)
4

0.76 (2.31)
0.72 (-0.55, 1.77)
1

*0.0348
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Average Waist
Circumference
Mean (SD)
Median (IQR)
Missing

1.72 (5.36)
1.63 (-1.60, 5.50)
3

2.37 (5.93)
1.90 (-1.00, 5.60)
1

0.6362

0.01 (0.09)
0.01 (-0.02, 0.03)
3

0.00 (0.05)
0.00 (-0.02, 0.03)
1

0.7641

0.78 (6.15)
0.36 (-2.30, 3.60)
4

1.70 (5.95)
1.74 (-2.10, 5.10)
1

0.1075

-0.15 (1.15)
-0.20 (-0.90, 0.5)
4

-0.36 (1.59)
-0.30 (-1.00, 0.3)
0

0.3996

Waist/Hip Ratio
Mean (SD)
Median (IQR)
Missing

Weight (in. Kg)
Mean (SD)
Median (IQR)
Missing

Height (in cm.)
Mean (SD)
Median (IQR)
Missing

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR, which is the 75th-25th percentile contrast.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
Table 19: The Change in Glucoregulatory Characteristics between Visits 1 & 2 When Measured
amongst Participants with IGT at Baseline
Characteristics*

Reversal from
IGT to NGT
(N=81)

No Transition
to NGT
(N=222)

P-Value
(For the
comparison
of change
between the
groups)

2.80 (9.65)
3.00 (-2.0, 7.0)
0

2.98 (26.33)
5.00 (-2.0, 10.0)
2

0.1291

-15.87 (107.31)
-7.50(-52.0, 27.0)
3

30.34 (113.52)
9.00 (-25.0, 65.0)
6

*0.0032

Fasting Insulin
(uU/mL)
Mean (SD)
Median (IQR)
Missing

2 Hr Insulin
(uU/mL)
Mean (SD)
Median (IQR)
Missing

Si value
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Mean (SD)
Median (IQR)
Missing

-0.31 (1.80)
-0.26(-0.74, 0.25)
14

-0.36 (1.53)
-0.33 (-0.95, 0.0)
45

0.1723

0.0 (0.01)
-0.0 (-0.01, 0.01)
14

-0.00 (0.01)
-0.0 (-0.01, 0.00)
46

0.6576

192.23 (556.17)
52.82 (-87.73,
374.64)
13

-59.52 (273.94)
-32.09 (-145.55,
68.09)
39

*0.0007

-2.34 (10.45)
-1.50 (-7.5, 4.5)
0

15.48 (34.53)
6.50 (-2.0, 17.50)
3

* <.0001

-35.81 (20.56)
-30.5 (-48.0, -19)
2

45.94 (68.03)
28.25 (2.0, 72.0)
4

*<.0001

Sg value
Mean (SD)
Median (IQR)
Missing

AIR from MINMOD
Mean (SD)
Median (IQR)
Missing

Fasting Glucose
(mg/dL)
Mean (SD)
Median (IQR)
Missing

2 Hr Glucose
(mg/dL)
Mean (SD)
Median (IQR)
Missing

• All continuous variables are reported with the mean, standard deviation, median, and IQR.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
Table 20: The Change in the Lipid Profile Occurring between Visits 1 & 2 When Measured
amongst Participants with IGT at Baseline
Participant
Characteristics*

Reversal from IGT to
NGT (N=81)

No Transition
to NGT
(N= 222)

P-Value
(For the comparison
of change between
the groups)

-6.38 (32.14)
-2.50 (-28.00, 10.00)
7

-6.08 (30.51)
-3.50 (-23.0, 11.0)
8

0.7460

1.96 (9.49)
3.00 (-4.00, 7.00)
7

1.22 (11.31)
1.00 (-3.00, 7.00)
7

0.8737

Tot Chol (mg/dL)
Mean (SD)
Median (IQR)
Missing

HDL (mg/dL)
Mean (SD)
Median (IQR)
Missing
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LDL (mg/dL)
Mean (SD)
Median (IQR)
Missing

-9.31 (28.86)
-8.00 (-27.00, 6.00)
10

-9.50 (31.05)
-9.00 (-27.0, 10.0)
17

0.6706

-16.78 (70.04)
-10.00 (-37.00, 12.00)
7

-7.46 (78.33)
-3.00 (-36.0, 31.0)
7

0.1505

-0.00 (0.00)
-0.00 (-0.01, 0.00)
25

-0.00 (0.00)
-0.00 (-0.00, 0.00)
42

0.1275

-0.00 (0.02)
-0.00 (-0.01, 0.00)
25

-0.00 (0.02)
-0.00 (-0.01, 0.00)
42

0.0881

-0.00 (0.01)
-0.00 (-0.00, 0.00)
25

-0.00 (0.01)
-0.00 (-0.01, 0.00)
42

0.0755

-0.00 (0.01)
-0.00 (-0.00, 0.00)
25

-0.00 (0.01)
-0.00 (-0.01, 0.00)
42

0.0684

0.0 (0.00)
0.0 (-0.00, 0.00)
25

0.0 (0.00)
0.00 (-0.00, 0.00)
42

0.8480

Trigs (mg/dL)
Mean (SD)
Median (IQR)
Missing

Ratio of
(iPF_2a)/BMI
Mean (SD)
Median (IQR)
Missing

Ratio of
(ipf2_ng_mg_cn)/B
MI
Mean (SD)
Median (IQR)
Missing

Ratio of
(Iso_iPF_2a)/BMI
Mean (SD)
Median (IQR)
Missing

Ratio of
(Dinor_ng_mg_cn)
/BMI
Mean (SD)
Median (IQR)
Missing
Ratio of F2-IsoP
Index/BMI1
Mean (SD)
Median (IQR)
Missing

Note: The index is simply the mean of four standardized F2-isoprostanes.1
• All continuous variables are reported with the mean, standard deviation, median, and IQR.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
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Table 21: The Change in the Cardiovascular Characteristics Occurring between Visits 1 & 2
When Measured amongst Participants with IGT at Baseline
Participant
Characteristics*

Reversal from
IGT to NGT
(N=81)

No Transition to
NGT
(N= 222)

P-Value
(For the comparison of
change between the
groups)

26 (32.50%)
4 (5.00%)
9 (11.25%)
41 (51.25%)
1

87 (39.37%)
6 (2.71%)
36 (16.29%)
92 (41.63%)
1

0.2674

-0.09 (0.14)
-0.07 (-0.17, -0.0)
3

-0.07 (0.13)
-0.06 (-0.15, 0.01)
1

0.4199

0.12 (0.30)
0.03 (-0.06, 0.16)
10

0.07 (0.44)
0.02 (-0.09, 0.18)
34

0.4143

0.00 (0.13)
-0.0 ( -0.06, 0.07)
6

0.05 (0.16)
0.03 ( -0.04, 0.12)
24

*0.0369

6.97 (17.27)
7.00 (0.00, 14.0)
6

5.86 (15.97)
7.00 ( -4.00, 15.00)
17

0.5908

-0.45 (9.71)
0.00 ( -6.0, 6.00)
6

0.75 (9.26)
1.00 ( -6.00, 7.00)
14

0.6406

Hypertension
High-High N (%)
High-Normal N (%)
Normal-High N (%)
Normal-Normal N (%)
Missing

Ankle/Brachial Index
Mean (SD)
Median (IQR)
Missing
Mean Internal Carotid
Artery Far Wall Max.
Mean (SD)
Median (IQR)
Missing
Mean Common Carotid
Artery Far Wall Max.
Mean (SD)
Median (IQR)
Missing

Systolic
(Ave 2&3)
Mean (SD)
Median (IQR)
Missing

Diastolic
(Ave 2&3)
Mean (SD)
Median (IQR)
Missing

•

All continuous variables are reported with the mean, standard deviation, median, along with
the IQR.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical
variables.
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Table 22: The Change in Lifestyle Characteristics occurring between Visits 1 & 2 When
Measured amongst Participants with IGT at Baseline
Participant
Characteristics*

Reversal from
IGT to NGT
(N=81)

No Transition to
NGT (N= 222)

P-Value
(For the
comparison
of change
between the
groups)

36 (44.44%)
2 (2.47%)
2(2.47%)
26 (32.10%)
2 (2.47%)
0 (0.00%)
5 (6.17%)
8 (9.88%)

102 (46.36%)
3 (1.36%)
5 (2.27%)
80 (36.36%)
3 (1.36%)
0 (0.00%)
13 (5.91%)
14 (6.36%)

0.8254

-276.94
(2617.78)
-400.0 (-1568.0,
776.0)
2

-267.52
(2666.31)
-228.00 (-1520.00,
978.00)
6

0.6273

Smoking Status
Never- Never N (%)
Never- Ex N (%)
Ex- Never N (%)
Ex- Ex. N (%)
Ex- Current N (%)
Current- Never N (%)
Current- Ex. N (%)
Current-Current N
(%)

Mod. Energy
Expended
(kcal/kg/yr)
Mean (SD)
Median (IQR)
Missing
Total Energy
Expended
(kcal/kg/yr)
Mean (SD)
Median (IQR)
Missing
High Energy
Expended
(kcal/kg/yr)
Mean (SD)
Median (IQR)
Missing

0.5323
-187.31
(1976.92)
-290.63
-1107.38, 558.0)
2

-165.12 (3185.60)
-162.63
(-1197.38,
1012.00)
7

-37.22 (1587.39)
0.00 (-404.00,
216.00)
2

5.49 (3007.07)
0.00 (-384.0,
260.0)
7

0.9468

*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test; the Wald chi-square test was utilized for the remaining categorical
variables.
• All continuous variables are reported with the mean, standard deviation, median, along with
the IQR.
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Table 23: The Change in the Urinary Biomarkers Occurring between Visits 1 & 2 When
Measured amongst Participants with IGT at Baseline
Participant
Reversal from IGT to
Characteristics* NGT (N=81)

No Transition to NGT
(N= 222)

P-Value
(For the
comparison
of change
between
the groups)

-21.58 (90.85)
-7.70 (-64.90, 32.50)
3

-5.26 (90.85)
-6.20 (-56.50, 48.70)
7

0.3887

1.56 (17.65)
-0.20 (-0.40, 2.50)
3

38.51 (378.19)
-0.20 (-0.40, 5.10)
8

0.6372

Urine
Creatinine
(mg/dL)
Mean (SD)
Median (IQR)
Missing

Urine Albumin
(mg/L)
Mean (SD)
Median (IQR)
Missing

• All continuous variables are reported with the mean, standard deviation, median, and IQR.
*Differences between groups for continuous variables were assessed using the Wilcoxon Rank
Sum/Kruskal Wallis Test.
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CHAPTER V
DISCUSSION
5.1 Discussion of the Research Question
Due to a dearth of RCTs within this specific area of diabetes research, the purpose of this
study is to discover characteristics that may help to induce a reversal from a state of IGT back to
one of NGT. This study takes a novel approach by using exploratory data analysis (EDA) in
order to evaluate findings obtained from the Insulin Resistance Atherosclerosis Study (IRAS)
cohort. In addition to the lack of extant studies examining the reversal from prediabetes to a state
of NGT, those that are in existence focus specifically upon lifestyle and/or medication
interventions.19 The findings generated from some of these extant studies are mixed, with
efficacity waning over time in some instances—particularly in relation to the use of medications
and lifestyle regimens.20 In order to acquire more information on that which may aid in the
reversal from IGT to NGT, this study delves into several previously unexplored areas through
the inclusion of the following: measures of adiposity, the lipid profile, cardiovascular
characteristics, glucoregulatory mechanisms, along with anthropometric, lifestyle, and
demographic characteristics of interest. This study goes one step further by attempting to
understand the interplay of the potential factors that may be involved in this reversal when
measured in simultaneity, which may help to stimulate future research studies due to the
potential for synergistic effects.
The first hypothesis centers upon the notion that demographic characteristics—sex,
ethnicity, menopausal status, and age-- may serve as predictors of a reversal from a state of
prediabetes (or IGT) back to one of NGT. The results of this study revealed that menopausal
19
20

These have ultimately produced varied results in terms of success.
such as exercise routines.
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status and gender 21 are statistically significant; men were more likely to reverse from IGT back
to NGT relative to their female counterparts—an outcome that runs contrary to previous
research.
The second research hypothesis relating to the impact that anthropometric measures have
upon a regression from IGT to NGT yielded mixed findings. While adults with higher BMIs
were significantly less likely to transition from a state of IGT to NGT relative to those with
lower BMIs, there were no significant differences across groups for the average waist
circumference, waist/hip ratio, and weight. We conjectured that changes in glucoregulatory
characteristics would engender a reversal from a state of IGT to one of NGT. While the study did
find statistically significant outcomes for 2-hr insulin, AIR from MINMOD, fasting glucose, and
2-hr glucose, this was not the case for insulin sensitivity (SI), glucose effectiveness (SG), or for
fasting insulin. Decreases in 2-hr insulin, fasting glucose, 2-hr glucose levels, and a higher AIR
did incite a regression from a state of IGT to one of NGT, whereas there were no statistically
significant findings emerging across groups for changes in SI, SG, and fasting insulin when
measured over the five-year time frame.
We also hypothesized that changes in the lipid profile over time, which is comprised of
total cholesterol, HDL and LDL levels, triglyceride levels, and the ratio of all four F2isoprostanes divided by BMI, would serve as predictors facilitating the transition from IGT back
to an improved state of NGT. Since no statistically significant results were produced, this did not
lend support to the findings from the current landscape of research regarding the lipid profile.
This runs counter to the results found in the current existing literature in which lower levels of

21

This comes as no surprise given that menopausal status is nested within gender and in turn
applies only to female participants.
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triglycerides and LDL cholesterol (when accompanied by a higher supply of HDL cholesterol)
were found to prompt a transition from a state of prediabetes back to one of NGT.
The fifth research hypothesis posits that cardiovascular risk factors--hypertension, the
ankle/brachial index, systolic and diastolic measures of blood pressure, mean CCA, and the mean
ICA--aid in the reversal from a state of prediabetes to one of NGT. However, since none of these
variables generated statistically significant findings, this suggests that these cardiovascular
characteristics may be inadequate predictors of a reversal from a state of IGT to one of NGT.
The sixth research hypothesis seeks to evaluate the impact (if any) that lifestyle
characteristics (such as energy expenditure and smoking status) have upon the potential for
regression from a state of IGT to one of NGT. In a manner similar to cardiovascular risk factors,
no statistically significant differences emerged with regard to lifestyle characteristics. Smoking
status along with the variant types of energy expenditures (which were total, moderate, and high)
did not successfully predict the onset of a transition from a state of IGT to one of NGT. The
final hypothesis seeks to measure the impact of urine creatinine and urine albumin upon the
potential for reversal from a prediabetic state back to one of NGT. Since no statistically
significant findings arose for urinary biomarkers, this result indicates that urine albumin and
urine creatinine were not effective predictors of a regression from a state of IGT to one of NGT.
When testing for statistical significance, the outcomes for demographic and adiposity
measures produced mixed results.22 The findings obtained for BMI in this study mirrors results
that were found in the POP-ABC analysis from 201423 in that a lower BMI is an effective
predictor in the ability to transition from IGT back to a state of NGT [1]. The reverse similarly
held true in that in that those with higher BMIs were less likely to regress from a state of IGT to
22
23

in terms of regressing from a state of IGT to NGT as measured in the context of this study.
by Dagogo-Jack et. al.
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one of NGT and instead were more likely to transition from IGT towards the onset of full-blown
T2D.
While the outcome found for BMI corroborated finding from existing research, findings
for gender in this study ran contrary to that which is in the current background of prediabetes
literature. This study found that men were more likely to achieve a successful regression from a
state of IGT back to one of NGT, whereas the reverse held true for their female counterparts.
Despite the unexpected nature of the outcome found for gender, this was supported by the
statistically significant results found for menopausal status.24 These findings are notable in that
they highlight a predisposition that female subjects may have given that they appeared to
transition from a state of prediabetes (or IGT) to overt type 2 diabetes more frequently than their
male peers. This outcome suggests that some of the underlying mechanisms relating to gender
may not yet be fully understood. As a result, these conflicting findings merit additional research
in order to fully address the underpinnings that at this point remain both poorly understood and
minimally studied.
The results acquired in this study may vary slightly in comparison to some of the findings
from previously existing research due to several considerations. One reason for this could be due
to the sample size being comprised of only 303 individuals. Participants met the inclusion
criteria only if they were categorized as being in a state of IGT when measured at baseline,
which subsequently led to a small sample size. With only 303 participants being classified as
having IGT upon visit 1, this small n-size may in turn serve as a limitation. Another potential
explanation that may account for the discrepancies in terms of what was deemed to be of

24

When measured at baseline and again at follow-up in the context of our current study.
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statistical significance 25 may be due to the criteria utilized and codified by researchers
accountable for the implementation and analysis of the Insulin Resistant Atherosclerosis Study.
The specific criteria used may influence the number of participants who were categorized as
being in a state of IGT in addition to affecting the the number of subjects who were potentially
discounted from being classified as prediabetic as well. The criteria used for the purpose of this
study are based on measuring impaired glucose tolerance (IGT) using the oral glucose tolerance
test (OGTT) along with the frequently sampled intravenous glucose tolerance test (FSIGT) [10].
While the OGTT and the FSIGT are commonly utilized procedures, one potential concern is that
the results from the IRAS data set may differ from those found in other studies due to manner in
which both IGT and NGT are operationally defined. More specifically, the operational
definitions and criteria used can impact the overall findings by influencing the statistical
significance of the variables chosen. Another consideration is that the decision of whether to
accept or reject the null hypothesis may differ across studies based upon the significance levels
and/or confidence intervals used.26
5.2 Study Strengths and Limitations
The prospective cohort study design exemplified by the insulin resistance atherosclerosis
study (IRAS) is a powerful tool. It is a rare opportunity through which to evaluate changes
occurring over time for a wide assortment of characteristics in order to find potential predictors
that may incite a reversal from a state of IGT to one of NGT. A strength of this study is that
analyzing the cohort from the IRAS data set allows for the observation of trends occurring over a
five-year time frame for an entire host of factors. The extensive number of variables contained
within the IRAS data set can ultimately set the stage for a wealth of associations between
25
26

in addition to the variables that were deemed to not be statistically significant.
Although this is rather unlikely.
68

variables to be analyzed over time in future research studies. Another strength of IRAS is that it
is the first epidemiologic study of its kind intended to evaluate relationships between factors such
as insulin resistance, insulinemia, glycemia, and the prevalence of cardiovascular disease (or
CVD) when assessed in the context of a large multiethnic cohort. Moreover, researchers went to
great lengths (and even oversampled) in an attempt to ensure as much equal representation as
possible across all respective levels of gender, race/ethnicity, geographic region, along with the
glucose tolerance status of participants.
Although the criteria and the operational definitions utilized in the IRAS to measure
glucose tolerance are widely accepted, the number of individuals who were characterized as
having IGT at baseline was limited (n=303). As a result, this rendered a generalizable conclusion
difficult to make and is accompanied by the inability to infer causality. Due to the unanticipated
results arising with regard to menopausal status, it is quite possible that there may be underlying
mechanisms or metabolic processes faced by female participants that have not yet been fully
understood or encapsulated and that merit future research. With respect to female subjects,
drawing conclusions regarding menopausal status and the potential for a transition in glucose
tolerance status is difficult to make on account of the small sample size (n=189) and as a result
the findings should be interpreted with caution. Nonetheless, the statistical methodology used in
this study to tackle this problem—Fisher’s Exact test—does account for this exceedingly small
sample size. This test helped to generate p-values that are more reflective of reality (despite the
small n-size) which is another strength of this study. Lastly, the use of exploratory data analysis
(EDA) sets the stage for future research that can build off of these preliminary results since this
study merely serves as a starting point.
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5.3 Conclusions and Recommendations
Despite the small sample size (n=303) of the cohort used in this study, the goal is to bring
attention to the importance of reversing prediabetes back to a state of NGT before these patients
ultimately transition from a state of IGT to T2D and the health-related damage incurred is
irreversible. The contradictory nature of some of the abovementioned findings and the lack of
statistical significance with regard to certain variables27 attest to the current paucity of studies
and serve as a testament for why further research needs to be conducted in this area in order to
bridge existing gaps. Novel research is needed to better understand the issues surrounding this
inadequately studied area of prediabetes and can also help in the creation of targeted
interventions aimed at mitigating dysglycemia and at restoring NGT.

27

that one would expect to serve as adequate predictors of a regression from a state of IGT to
NGT.
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